Valeant Pharmaceuticals is a very aggressive acquirer of companies and assets. The Canadian company has most recently purchased the rights to an asset from AstraZeneca in the area of psoriasis. The drug, brodalumab, was previously partnered with Amgen but the company exited the agreement from AstraZeneca earlier this year upon concerns of suicidal thoughts in patients enrolled in trials, allowing AZ to find a new partner for the late-stage asset.
The product inhibits IL-17, a cytokine that plays a key role in inflammatory and autoimmune diseases. The first of the IL-17 inhibitors was approved this year.
Valeant offered an upfront payment of $100 million to AstraZeneca, and additional milesstones nearing $350m for the psoriasis drug.
Regulatory submissions in the United States and Europe for brodalumab in moderate-to-severe psoriasis are planned for the fourth quarter of 2015.Fifty Shades Darker film download